{"artifact":{"id":"open_question-bfd76775-efe5-4c91-947d-510b6db29a1f","artifact_type":"open_question","entity_ids":"[\"therapeutics\"]","title":"Timing of intervention**: Preclinical vs. symptomatic stages of disease?","quality_score":0.5,"created_by":"backfill_open_questions","provenance_chain":"[]","content_hash":"63016bd0675540a9c810c1218610f8b366afc7129e29ec968790ef7df2b997bc","metadata":{"status":"open","_origin":{"url":null,"type":"internal","tracked_at":"2026-04-26T03:27:33.041501"},"field_tag":"therapeutics","source_id":"therapeutics-p2x7-receptor-antagonists-neurodegeneration","sub_field":"p2x7-receptor-antagonists-neurodegeneration","source_kind":"wiki","question_hash":"f7955d90e3d231851a0073e336038f34ba899cdd1072b9f2c6bb3cb1c77bcb89","question_text":"Timing of intervention**: Preclinical vs. symptomatic stages of disease?","importance_elo":1500,"_schema_version":1,"evidence_summary":"Extracted from wiki page therapeutics-p2x7-receptor-antagonists-neurodegeneration","tractability_score":0.5,"potential_impact_score":0.5},"created_at":"2026-04-25T20:27:33.041686-07:00","updated_at":"2026-04-25T20:27:33.041686-07:00","version_number":4,"parent_version_id":null,"version_tag":null,"changelog":null,"is_latest":1,"lifecycle_state":"active","superseded_by":null,"deprecated_at":null,"deprecated_reason":null,"dependencies":null,"market_price":0.5,"origin_type":"internal","origin_url":null,"lifecycle_changed_at":"2026-04-25T20:27:33.041686-07:00","citation_count":0,"embed_count":0,"derivation_count":0,"support_count":0,"contradiction_count":0,"total_usage":0.0,"usage_score":0.5,"usage_computed_at":null,"quality_status":null,"contributors":[],"answers_question_ids":null,"deprecated_reason_detail":null,"deprecated_reason_code":null,"commit_sha":null,"commit_submodule":null,"last_mutated_at":"2026-05-16T14:51:34.657673-07:00","disputed_at":null,"gap_id":null,"mission_id":null,"intrinsic_priority":null,"effective_priority":null,"artifact_id":"00785bbb-8332-4777-9bb1-093ede039919","artifact_dir":null,"primary_filename":null,"accessory_filenames":null,"folder_layout_version":1,"migrated_to_folder_at":null,"hypothesis_id":null,"authorship":{"kind":"human","contributors":[{"role":"author","actor_ref":"backfill_open_questions"}]},"epistemic_tier":"T3_provisional","created_by_agent_id":null},"outgoing_links":[{"target_artifact_id":"wiki-therapeutics-p2x7-receptor-antagonists-neurodegeneration","link_type":"derives_from","strength":0.9,"evidence":"{\"method\": \"open_question_wiki_crosslink\", \"cycle\": \"artifact-enrichment-2026-04-27\"}"}],"incoming_links":[],"current_artifact_id":"open_question-bfd76775-efe5-4c91-947d-510b6db29a1f","is_canonical":true,"supersede_chain":["open_question-bfd76775-efe5-4c91-947d-510b6db29a1f"]}